Psychotic Disorders - Canada | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$233.30m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.62%, resulting in a market volume of US$240.70m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$491.90 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Canada is experiencing significant growth and development due to several key factors.

Customer preferences: Customers in Canada are increasingly seeking effective treatments and therapies for psychotic disorders. They are looking for medications that can effectively manage symptoms and improve their quality of life. Additionally, there is a growing demand for non-pharmacological interventions, such as cognitive behavioral therapy, to complement medication-based treatments.

Trends in the market: One of the major trends in the Psychotic Disorders market in Canada is the increasing use of atypical antipsychotic medications. These medications have been shown to be more effective and have fewer side effects compared to traditional antipsychotics. As a result, there has been a shift towards prescribing atypical antipsychotics as the first-line treatment for psychotic disorders. This trend is driven by the desire to provide patients with the best possible outcomes and minimize adverse effects.Another trend in the market is the growing adoption of digital health technologies for the management of psychotic disorders. Mobile applications and online platforms are being developed to provide patients with self-management tools, access to support networks, and remote monitoring of symptoms. These technologies have the potential to improve patient engagement, enhance treatment adherence, and enable more personalized care.

Local special circumstances: Canada has a publicly funded healthcare system, which ensures that all residents have access to essential healthcare services, including treatments for psychotic disorders. This universal healthcare coverage contributes to the growth of the Psychotic Disorders market in Canada, as it eliminates financial barriers to accessing treatment and encourages early intervention.Furthermore, Canada has a well-established network of mental health professionals and research institutions that contribute to the development and advancement of treatments for psychotic disorders. This expertise and collaboration between healthcare providers, researchers, and pharmaceutical companies drive innovation and contribute to the growth of the market.

Underlying macroeconomic factors: The growth of the Psychotic Disorders market in Canada is also influenced by macroeconomic factors. Canada has a stable economy with a high standard of living, which allows for increased healthcare spending. The government's commitment to mental health and the recognition of the impact of psychotic disorders on individuals and society further support investment in the market.Additionally, the aging population in Canada is contributing to the growth of the market. Psychotic disorders, such as schizophrenia, often emerge in early adulthood and have a chronic course. As the population ages, the prevalence of these disorders is expected to increase, driving the demand for treatments and therapies.In conclusion, the Psychotic Disorders market in Canada is experiencing growth and development due to customer preferences for effective treatments and non-pharmacological interventions. The trends in the market include the increasing use of atypical antipsychotics and the adoption of digital health technologies. Local special circumstances, such as universal healthcare coverage and a strong network of mental health professionals and research institutions, contribute to the growth of the market. Furthermore, underlying macroeconomic factors, such as a stable economy and an aging population, support the expansion of the market.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.